MedTrace Logo

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

NCT04366830 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2021-02-18

No results posted yet for this study

Summary

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).

Conditions

  • Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19

Interventions

DRUG

Remestemcel-L

Participants will receive remestemcel-L in two infusions of 2 x 10\^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).

Sponsors & Collaborators

  • Mesoblast International Sàrl

    lead INDUSTRY

Principal Investigators

  • Elizabeth Burke, ANP-C · Mesoblast, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04366830 on ClinicalTrials.gov